A pre-approval inspection in the pharmaceutical industry is conducted to: Response:

Question

Options

• AEvaluate the overall financial health of the manufacturing firm.
• BAssess the manufacturing site's compliance with regulatory standards before product approval.
• CInvestigate a specific complaint or adverse event.
• DConfirm the effectiveness of a new marketing strategy.

• A
  8% (2)
• B
  83% (20)
• C
  4% (1)
• D
  4% (1)

Explanation

Option B is correct because a pre-approval inspection (PAI) is a regulatory agency visit (e.g., FDA) to a manufacturing site before a new drug product is approved - its purpose is to verify that the facility can consistently manufacture the product in compliance with Good Manufacturing Practices (GMP) and that data submitted in the application is accurate.

Why the distractors are wrong:

• A (financial health) - Regulatory agencies assess manufacturing and quality compliance, not business finances; that's the domain of investors or auditors.
• C (complaint/adverse event) - That describes a for-cause or surveillance inspection, which is reactive; a PAI is proactive and tied to an application under review.
• D (marketing strategy) - Regulatory inspections have no involvement in marketing; that falls under commercial/business functions entirely outside GMP oversight.

Memory tip: Break down the name itself - Pre (before) + Approval (drug application decision) + Inspection (regulatory site visit) = "Can this site make the drug properly before we say yes?" This distinguishes it from post-market inspections, which happen after approval.

No community discussion yet for this question.